April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Glucocorticoid Receptors in Light-Induced Retinal Degeneration
Author Affiliations & Notes
  • M. A. Cubilla
    Cell and Molecular Medicine, Ciencias Biomedicas. Universidad Austral, Pilar, Argentina
  • M. M. Castañeda
    Cell and Molecular Medicine, Ciencias Biomedicas. Universidad Austral, Pilar, Argentina
  • G. A. Luzzani
    Cell and Molecular Medicine, Ciencias Biomedicas. Universidad Austral, Pilar, Argentina
  • A. M. Suburo
    Cell and Molecular Medicine, Ciencias Biomedicas. Universidad Austral, Pilar, Argentina
  • Footnotes
    Commercial Relationships  M.A. Cubilla, None; M.M. Castañeda, None; G.A. Luzzani, None; A.M. Suburo, None.
  • Footnotes
    Support  MINCYT PICT 21399/2004
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2258. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. A. Cubilla, M. M. Castañeda, G. A. Luzzani, A. M. Suburo; Glucocorticoid Receptors in Light-Induced Retinal Degeneration. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2258.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Glucocorticoids (GCs) block photoreceptor cell death in inherited and light-induced retinal degenerations. Steroids can exert potent antiapoptotic effects through different pathways. However, GC-dependent survival pathways in the retina are still controversial. Therefore we evaluated the effects of GC receptor (GR) inhibition on light-induced photoreceptor degeneration and sought a correlation between these effects and levels of the antiapoptotic protein Bcl-XL.

Methods: : Experimental work was done according to the ARVO Statement for the use of animals. Male Balb-c mice (35-45 days-old), bred under standard illumination conditions (12:12 h light: dark; < 60 lux), remained in complete darkness for 24 h. They were divided in two groups: those returning to standard illumination, and those exposed to 1,500 lux during 2-4 days. Animals from both groups received mifepristone (MFP, a GR inhibitor) or dexamethasone (DEX) or saline. Photoreceptor degeneration was evaluated by histology, cleaved caspase-3 (CC3) immunostaining and opsin protein levels. GR and Bcl-XL was immunochemically detected in cryosections and Western blots.

Results: : In normal mice, GR-ir appeared in cell nuclei from all retinal layers. Light-exposed retinas showed stronger immunostaining. After 2 days under 1,500 lux, retinas displayed shortening of photoreceptor outer segments and decreased opsin. Damage after 4 days included loss of photoreceptor cell nuclei and decrease of opsin below detection levels. Opsin decrease at 2 days was prevented by DEX and increased by MFP administration. GR inhibition also increased the number of CC3+ cell nuclei. Opsin levels were unchanged in animals remaining under standard illumination, with or without DEX or MPF administration.Animals exposed to 1,500 lux during 4 days and returned to standard illumination for another 6 days showed partial recovery of opsin levels. Opsin recovery did not occur in mice receiving MFP during light exposure.Bcl-XL levels decreased after 2 days under 1,500 lux. This effect was prevented by DEX. Administration of MFP determined a large reduction of Bcl-XL levels, even in animals remaining under standard illumination.

Conclusions: : Our observations indicate that MFP increased photoreceptor damage and death after exposure to toxic light levels. GR-mediated activation of the antiapoptotic molecule Bcl-XL would be an important component of photoreceptor response to light injury. Retinas deficient in Bcl-XL might be abnormally sensitive to apoptotic stimuli.

Keywords: photoreceptors • retinal degenerations: cell biology • apoptosis/cell death 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×